NZ Malignant Haematology Research Review Issue 1

In this issue:
  -  Adding ibrutinib to R-CHOP in DLBCL with BCL2-MYC co-expression
  -  History of idelalisib in indolent non-Hodgkin lymphoma
  -  Venetoclax and idasanutlin in relapsed/refractory AML
  -  Dabrafenib + trametinib in relapsed/refractory BRAF V600E HCL
  -  Atezolizumab + R-CHOP in previously untreated DLBCL
  -  Ide-cel vs. standard regimens in relapsed/refractory MM
  -  Optimising lenalidomide maintenance for MM by extended genetic profiling
  -  Auto vs. allo SCT in primary plasma cell leukaemia
  -  Impact of time between induction and auto transplant in newly diagnosed MM
  -  Interventions and outcomes in MM receiving salvage after anti-BCMA CAR T-cells

Please login below to download this issue (PDF)